Media Centre - EORTC
Immunocore Holdings plc - ADR Aktie News
SEC Filing :: Immunocore PLC
Rockville Nights: Rockville biotech firm Immunocore wins Prix Galien France award
Immunocore (NASDAQ:IMCR) Price Target Increased to $86.00 by Analysts at Mizuho - MarketBeat
RxTROSPECT — Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable
Immunocore's Kimmtrak (tebentafusp) Receives the EC's Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma
Immunocore and BMS partner to investigate first-line treatment for melanoma - Pharmaceutical Technology
Immunocore names David Berman as Head of R&D
Lilly and Immunocore Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies
Immunocore announces proposed convertible senior notes offering (NASDAQ:IMCR) | Seeking Alpha
Immunocore Reports First Quarter 2021 Financial Results
Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
image00001.jpg
AGC Biologics to Prepare Late-Phase and Commercial Runs for Immunocore
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 3
Using bispecifics to treat infectious disease
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation | IMCR Stock News
Immunocore inks deal on gamma delta (γδ) TCR ImmTAC for solid tumors
